Scientific publications

Expert recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD).

Alda JA (1), Soutullo C [SP] (2), Ramos-Quiroga JA (3), Quintero J (4), Hervás A (5), Hernández-Otero I (6), Sans-Fitó A (7), Cardo-Jalón EC (8), Fernández-Jaén A (9), Fernández-Pérez M (10), Hidalgo-Vicario MI (11), Eddy-Ives LS (12), Sánchez J (13).
(1) Servicio de Psiquiatría y Psicología, Hospital Sant Joan de Déu, Barcelona.
(2) Unidad de Psiquiatría Infantil y Adolescente, Departamento de Psiquiatría y Psicología Médica, Clínica Universidad de Navarra.
(3) Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron / CIBERSAM / Universitat Autònoma de Barcelona.
(4) Servicio de Psiquiatría, Hospital Universitario Infanta Leonor en Madrid. Departamento de Psiquiatría. Universidad Complutense de Madrid.
(5) Unitat especialitzada en trastorns del desenvolupament (UETD), Hospital Sant Joan de Déu. Servicio de Psiquiatría Infantil y juvenil, Hospital Universitario Mutua de Terrassa. Barcelona.
(6) Unidad de Salud Mental Infanto-Juvenil, Hospital Clínico Universitario Virgen de la Victoria de Málaga.
(7) Unidad de Trastornos del Aprendizaje (UTAE), Servicio de Neurología, Hospital Sant Joan de Déu Esplugues de Llobregat, Barcelona.
(8) Servicio Neuropediatría, Hospital Son Llatzer, Baleares. Universidad Islas Baleares.
(9) Unidad de Neurología Infantil, Hospital Universitario Quirón de Madrid.
(10) Centro de Salud de La Felguera, Asturias.
(11) Centro de Salud Barrio del Pilar. D.A. Norte. SERMAS. Madrid.
(12) Centre Mèdic Sant Ramon. Unidad Clínica Fundación Adana. Barcelona.
(13) Departamento Médico, Shire Pharmaceuticals Ibérica. Madrid. 

Magazine: Actas Españolas de Psiquiatría

Date: Dec 1, 2014

Child and Adolescent Psychiatry Unit [SP] Psychiatry and Clinical Psychology [SP]

ABSTRACT

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobiological disorders in childhood, and is characterized by inappropriate levels of inattention, hyperactivity and/or impulsiveness, with an estimated prevalence of 5.29%.

ADHD can have a negative impact upon all areas of the life of the patient. The main clinical guides accept multimodal treatment, involving both pharmacological and psychological measures, as the best management approach in ADHD (psychoeducational, behavioural and academic).

Lisdexamfetamine dimesylate (LDX) is a new drug for the treatment of ADHD. A multidiscipline expert document has been developed, compiling the scientific evidence referred to this new molecule.

The study also addresses the existing shortcomings in current drug therapy for ADHD and the contributions of LDX to routine clinical practice, in an attempt to help and guide physicians in the use of this new treatment.

This document is endorsed by the ADHD and Psychoeducational Development task Group of the Spanish Society of Primary Care Pediatrics (Grupo de TDAH y Desarrollo Psicoeducativo de la Asociación Española de Pediatría de Atención Primaria, AEPap), the Spanish Society of Pediatric Neurology (Sociedad Española de Neurología Pediátrica, SENEP) and the Spanish Society of Out-hospital Pediatrics and Primary Care (Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria, SEPEAP).

CITATION  Actas Esp Psiquiatr. 2014 Dec;42 Suppl:1-16. Epub 2014 Dec 1.

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra